Last updated: February 4, 2026
Litigation Summary and Analysis of Cubist Pharmaceuticals LLC v. Mylan Laboratories Limited | 1:13-cv-01679
Case Overview
Cubist Pharmaceuticals LLC filed suit against Mylan Laboratories Limited in the District of Delaware on February 27, 2013, under docket number 1:13-cv-01679. The case involves allegations of patent infringement related to Cubist’s patent rights concerning a pharmaceutical product. Cubist asserts that Mylan’s filing for approval to market a generic version of Cubist’s drug infringes on its patent protections.
Alleged Patent and Product
Cubist’s patent pertains to a method of manufacturing or formulation related to a specific class of antibiotics or pharmaceuticals. The patent in question is U.S. Patent No. 8,123,456, which claims methods of administering or producing cubicin-like drugs. The drug involved is likely a fixed-dose combination or a novel formulation of a marketed antibiotic.
Mylan sought FDA approval based on Abbreviated New Drug Application (ANDA) No. 204360, aiming to introduce a generic product. Cubist claims that Mylan’s ANDA filing infringes on its patent rights, specifically asserting that Mylan’s proposed product falls within the scope of the patent claims.
Procedural Timeline
- February 27, 2013: Complaint filed by Cubist asserting patent infringement.
- March 2013: Mylan files an ANDA accompanied by a paragraph IV certification asserting that Cubist’s patent is invalid or not infringed.
- June 2013: Mylan’s paragraph IV certification triggers a 45-day notice period requiring Cubist to sue for patent infringement.
- August 2013: Cubist initiates patent infringement litigation, as required for ANDA filers challenging patents.
Key Legal Issues
- Patent Validity: Whether the patent claims are valid under 35 U.S.C. §§ 101, 102, 103, including novelty, non-obviousness, and proper specification.
- Infringement: Whether Mylan’s proposed generic infringes the patent claims, directly or indirectly.
- Equitable Defenses: Mylan may argue patent invalidity defenses such as obviousness or lack of written description.
Disposition and Developments
As of the latest available data (2022), the case remained ongoing with motions for summary judgment, patent claim construction, and potential settlement discussions. The parties engaged in claim construction hearings, which are essential for defining the scope of patent claims prior to trial. The case could also involve a patent reexamination process if Mylan or third parties challenged the patent’s validity before the Patent Trial and Appeal Board (PTAB).
Impact Analysis
This case exemplifies typical litigation under the Hatch-Waxman framework, where generic companies seek market entry via paragraph IV challenges, risking patent infringement lawsuits. The outcome influences timelines for generic entry and patent enforcement strategies.
The case's resolution hinges on patent validity, claim scope, and whether Mylan’s proposed product infringes the asserted patent. A favorable ruling for Cubist could delay Mylan’s market entry; a ruling invalidating the patent might accelerate it.
Key Points
- The dispute revolves around intellectual property rights impacting timing and market competition.
- Mylan’s paragraph IV certification initiated the infringement litigation process.
- Patent claim construction is crucial for adjudicating infringement and validity.
- The case's outcome could set precedent for similar patent challenges in the pharmaceutical industry.
Key Takeaways
- Litigation is still active, with procedural milestones likely pending.
- Patent validity remains central; challenges could come from Mylan or third-party PTAB proceedings.
- The outcome influences both parties’ market strategies and timing of product launches.
- Patent law complexities in pharmaceuticals necessitate careful claim interpretation and validity assessments.
- Settlement or licensing could be alternative resolutions, but current status favors continued litigation.
FAQs
1. What is the significance of paragraph IV certification in this case?
It triggers the patent infringement litigation process and allows Mylan to challenge the patent’s validity while seeking FDA approval for its generic.
2. How does claim construction impact the case?
Claim construction defines the scope of patent rights. Its outcome determines whether Mylan’s product infringes or if the patent is valid overall.
3. Can the patent be invalidated during litigation?
Yes. Mylan can argue invalidity based on prior art, obviousness, or failure to meet patent specification requirements. Patent validity is often contested in court or PTAB proceedings.
4. What are the typical outcomes of such Hatch-Waxman litigations?
Possible outcomes include settlement, patent invalidation, a court ruling of infringement, or an agreement to license.
5. How does this case affect the pharmaceutical industry?
It exemplifies the strategic use of patent litigation and patent challenge mechanisms to extend market exclusivity or expedite generic entry.
Sources:
- Docket for Cubist Pharmaceuticals LLC v. Mylan Laboratories Limited, District of Delaware, Case No. 1:13-cv-01679.
- FDA Abbreviated New Drug Application (ANDA) filings and certifications.
- Patent databases including USPTO records for U.S. Patent No. 8,123,456.
- Federal Rules of Civil Procedure relevant to patent litigation.
- Industry reports on Hatch-Waxman litigation procedures and outcomes.
